Copyright Reports & Markets. All rights reserved.

Global Bacterial Vaginosis Drug Market Growth 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global Bacterial Vaginosis Drug Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Bacterial Vaginosis Drug Consumption 2014-2024
        • 2.1.2 Bacterial Vaginosis Drug Consumption CAGR by Region
      • 2.2 Bacterial Vaginosis Drug Segment by Type
        • 2.2.1 Rx
        • 2.2.2 OTC
      • 2.3 Bacterial Vaginosis Drug Consumption by Type
        • 2.3.1 Global Bacterial Vaginosis Drug Consumption Market Share by Type (2014-2019)
        • 2.3.2 Global Bacterial Vaginosis Drug Revenue and Market Share by Type (2014-2019)
        • 2.3.3 Global Bacterial Vaginosis Drug Sale Price by Type (2014-2019)
      • 2.4 Bacterial Vaginosis Drug Segment by Application
        • 2.4.1 Hospital
        • 2.4.2 Pharmacy
        • 2.4.3 Other
      • 2.5 Bacterial Vaginosis Drug Consumption by Application
        • 2.5.1 Global Bacterial Vaginosis Drug Consumption Market Share by Application (2014-2019)
        • 2.5.2 Global Bacterial Vaginosis Drug Value and Market Share by Application (2014-2019)
        • 2.5.3 Global Bacterial Vaginosis Drug Sale Price by Application (2014-2019)

      3 Global Bacterial Vaginosis Drug by Players

      • 3.1 Global Bacterial Vaginosis Drug Sales Market Share by Players
        • 3.1.1 Global Bacterial Vaginosis Drug Sales by Players (2017-2019)
        • 3.1.2 Global Bacterial Vaginosis Drug Sales Market Share by Players (2017-2019)
      • 3.2 Global Bacterial Vaginosis Drug Revenue Market Share by Players
        • 3.2.1 Global Bacterial Vaginosis Drug Revenue by Players (2017-2019)
        • 3.2.2 Global Bacterial Vaginosis Drug Revenue Market Share by Players (2017-2019)
      • 3.3 Global Bacterial Vaginosis Drug Sale Price by Players
      • 3.4 Global Bacterial Vaginosis Drug Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Bacterial Vaginosis Drug Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Bacterial Vaginosis Drug Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Bacterial Vaginosis Drug by Regions

      • 4.1 Bacterial Vaginosis Drug by Regions
        • 4.1.1 Global Bacterial Vaginosis Drug Consumption by Regions
        • 4.1.2 Global Bacterial Vaginosis Drug Value by Regions
      • 4.2 Americas Bacterial Vaginosis Drug Consumption Growth
      • 4.3 APAC Bacterial Vaginosis Drug Consumption Growth
      • 4.4 Europe Bacterial Vaginosis Drug Consumption Growth
      • 4.5 Middle East & Africa Bacterial Vaginosis Drug Consumption Growth

      5 Americas

      • 5.1 Americas Bacterial Vaginosis Drug Consumption by Countries
        • 5.1.1 Americas Bacterial Vaginosis Drug Consumption by Countries (2014-2019)
        • 5.1.2 Americas Bacterial Vaginosis Drug Value by Countries (2014-2019)
      • 5.2 Americas Bacterial Vaginosis Drug Consumption by Type
      • 5.3 Americas Bacterial Vaginosis Drug Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Bacterial Vaginosis Drug Consumption by Countries
        • 6.1.1 APAC Bacterial Vaginosis Drug Consumption by Countries (2014-2019)
        • 6.1.2 APAC Bacterial Vaginosis Drug Value by Countries (2014-2019)
      • 6.2 APAC Bacterial Vaginosis Drug Consumption by Type
      • 6.3 APAC Bacterial Vaginosis Drug Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Bacterial Vaginosis Drug by Countries
        • 7.1.1 Europe Bacterial Vaginosis Drug Consumption by Countries (2014-2019)
        • 7.1.2 Europe Bacterial Vaginosis Drug Value by Countries (2014-2019)
      • 7.2 Europe Bacterial Vaginosis Drug Consumption by Type
      • 7.3 Europe Bacterial Vaginosis Drug Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Bacterial Vaginosis Drug by Countries
        • 8.1.1 Middle East & Africa Bacterial Vaginosis Drug Consumption by Countries (2014-2019)
        • 8.1.2 Middle East & Africa Bacterial Vaginosis Drug Value by Countries (2014-2019)
      • 8.2 Middle East & Africa Bacterial Vaginosis Drug Consumption by Type
      • 8.3 Middle East & Africa Bacterial Vaginosis Drug Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Channels
        • 10.1.2 Indirect Channels
      • 10.2 Bacterial Vaginosis Drug Distributors
      • 10.3 Bacterial Vaginosis Drug Customer

      11 Global Bacterial Vaginosis Drug Market Forecast

      • 11.1 Global Bacterial Vaginosis Drug Consumption Forecast (2019-2024)
      • 11.2 Global Bacterial Vaginosis Drug Forecast by Regions
        • 11.2.1 Global Bacterial Vaginosis Drug Forecast by Regions (2019-2024)
        • 11.2.2 Global Bacterial Vaginosis Drug Value Forecast by Regions (2019-2024)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Bacterial Vaginosis Drug Forecast by Type
      • 11.8 Global Bacterial Vaginosis Drug Forecast by Application

      12 Key Players Analysis

      • 12.1 Bayer
        • 12.1.1 Company Details
        • 12.1.2 Bacterial Vaginosis Drug Product Offered
        • 12.1.3 Bayer Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.1.4 Main Business Overview
        • 12.1.5 Bayer News
      • 12.2 Pfizer
        • 12.2.1 Company Details
        • 12.2.2 Bacterial Vaginosis Drug Product Offered
        • 12.2.3 Pfizer Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.2.4 Main Business Overview
        • 12.2.5 Pfizer News
      • 12.3 Sanofi
        • 12.3.1 Company Details
        • 12.3.2 Bacterial Vaginosis Drug Product Offered
        • 12.3.3 Sanofi Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.3.4 Main Business Overview
        • 12.3.5 Sanofi News
      • 12.4 Piramal
        • 12.4.1 Company Details
        • 12.4.2 Bacterial Vaginosis Drug Product Offered
        • 12.4.3 Piramal Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.4.4 Main Business Overview
        • 12.4.5 Piramal News
      • 12.5 Abbott
        • 12.5.1 Company Details
        • 12.5.2 Bacterial Vaginosis Drug Product Offered
        • 12.5.3 Abbott Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.5.4 Main Business Overview
        • 12.5.5 Abbott News
      • 12.6 Galderma
        • 12.6.1 Company Details
        • 12.6.2 Bacterial Vaginosis Drug Product Offered
        • 12.6.3 Galderma Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.6.4 Main Business Overview
        • 12.6.5 Galderma News
      • 12.7 Mission
        • 12.7.1 Company Details
        • 12.7.2 Bacterial Vaginosis Drug Product Offered
        • 12.7.3 Mission Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.7.4 Main Business Overview
        • 12.7.5 Mission News
      • 12.8 Alkem
        • 12.8.1 Company Details
        • 12.8.2 Bacterial Vaginosis Drug Product Offered
        • 12.8.3 Alkem Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.8.4 Main Business Overview
        • 12.8.5 Alkem News
      • 12.9 Xiuzheng
        • 12.9.1 Company Details
        • 12.9.2 Bacterial Vaginosis Drug Product Offered
        • 12.9.3 Xiuzheng Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.9.4 Main Business Overview
        • 12.9.5 Xiuzheng News
      • 12.10 Teva
        • 12.10.1 Company Details
        • 12.10.2 Bacterial Vaginosis Drug Product Offered
        • 12.10.3 Teva Bacterial Vaginosis Drug Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.10.4 Main Business Overview
        • 12.10.5 Teva News
      • 12.11 Perrigo
      • 12.12 West-Ward
      • 12.13 HPGC
      • 12.14 Yunnan Baiyao
      • 12.15 Starpharma
      • 12.16 Novel
      • 12.17 Edenvridge

      13 Research Findings and Conclusion

      Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.
      The classification of bacterial vaginosis drug includes Rx and OTC, and the proportion of OTC in 2016 is about 72%.

      Bacterial vaginosis drug is widely sold in hospital, pharmacy and other field. The most proportion of bacterial vaginosis drug is sold in pharmacy, and the revenue in 2016 is about 423 M USD.

      USA region is the largest supplier of bacterial vaginosis drug, with a revenue market share nearly 32% in 2016. Europe is the second largest supplier of Bacterial Vaginosis Drug, enjoying revenue market share nearly 30% in 2016.

      USA and Europe are the largest consumption places, with the consumption market share nearly 28% in 2016.

      Market competition is intense. Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

      According to this study, over the next five years the Bacterial Vaginosis Drug market will register a 3.1% CAGR in terms of revenue, the global market size will reach US$ 970 million by 2024, from US$ 800 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Bacterial Vaginosis Drug business, shared in Chapter 3.

      This report presents a comprehensive overview, market shares, and growth opportunities of Bacterial Vaginosis Drug market by product type, application, key manufacturers and key regions and countries.

      This study considers the Bacterial Vaginosis Drug value and volume generated from the sales of the following segments:

      Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
      Rx
      OTC
      Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
      Hospital
      Pharmacy
      Other

      This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
      Bayer
      Pfizer
      Sanofi
      Piramal
      Abbott
      Galderma
      Mission
      Alkem
      Xiuzheng
      Teva
      Perrigo
      West-Ward
      HPGC
      Yunnan Baiyao
      Starpharma
      Novel
      Edenvridge

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Bacterial Vaginosis Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
      To understand the structure of Bacterial Vaginosis Drug market by identifying its various subsegments.
      Focuses on the key global Bacterial Vaginosis Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Bacterial Vaginosis Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the consumption of Bacterial Vaginosis Drug submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.

      Buy now